A. Fateeva

Toxicity and efficacy of biosimilar bevacizumab in the second-line therapy for metastatic colon cancer in routine clinical practice: results of an independent observational study

F. Moiseenko, O. Gladkov, A. Tryakin, 2021 .

Clinical and morphological features of breast tumors with PIK3CA mutations in Russian patients: Observational study

A. M. Degtyarev, R. Zukov, A. Vasilevskaya, 2022, Journal of Modern Oncology.

Search for predictors of the efficiency of treatment with CDK4/6 inhibitors with HR+/HER2 metastatic breast cancer

R. Zukov, V. Komissarova, A. Fateeva, 2023, Onkologiya. Zhurnal imeni P.A.Gertsena.